CNS Pharmaceuticals (CNSP) Maxim Group’s 2024 Healthcare Virtual Summit summary

Financial position and trial progress

• Successfully raised sufficient capital to fund operations through the completion of pivotal trial data expected in 2025.

• Overcame years of financing challenges, now in the strongest financial and operational position to date.

• Fully enrolled phase II/III trial for Berubicin in glioblastoma, with database lock anticipated this year and top-line data in Q1 2025.

• The trial is designed as a registrational study with FDA guidance, focusing on overall survival as the primary endpoint.

• Interim analysis by DSMB allowed the study to proceed without modification, indicating positive safety and efficacy signals.

Drug profile and clinical rationale

• Berubicin is a potent, blood-brain barrier-penetrant anthracycline, potentially non-cardiotoxic, and unique in its class.

• Low dosing is possible due to high potency, with no observed cardiotoxicity in clinical monitoring.

• The drug addresses a critical unmet need in recurrent glioblastoma, where current therapies are largely ineffective.

• If successful, Berubicin could expand to first-line treatment, especially for unmethylated patients lacking effective options.

• The drug's properties may allow future expansion into other brain metastases and anthracycline-sensitive cancers.

Competitive landscape and trial design

• The control arm uses Lomustine, with expectations that Berubicin can achieve a 20-25% improvement in overall survival.

• The trial is powered to detect meaningful differences, with 252 patients enrolled across 45 centers in eight countries.

• Lomustine's historical data may overstate its efficacy due to prior inclusion of astrocytoma patients; current trial includes only GBM.

• Even if primary endpoints are not met, fallback regulatory strategies are considered, especially for subgroups with high unmet need.

• The company is optimistic about approval prospects but acknowledges the inherent uncertainty in clinical outcomes.